Assessment of Jordanian Pharmacists’ Knowledge and Awareness of Liraglutide Injection and their Practice in Counseling Obesity Patients

Main Article Content

Dr.Jumanah Al-Shawabkeh

Keywords

GPL-1 receptor agonists, Saxenda®, Liraglutide injection 3 mg, Obesity, pharmacists , knowledge

Abstract

Background: The purpose of this study was to examine how pharmacists in Jordan perceive and make use of antidiabetic drugs, particularly Glucagonlike peptide-1 receptor agonists (e.g., Saxenda®), for body weight loss. Method: A reliability-validated online survey was created and sent out to the pharmacist’s community in Jordan to fill out and get knowledge about the use of Liraglutide injection. Social media was used to extend the survey to facilitate contact among pharmacists from multiple parts of the community. Results: A total of 395 pharmacists were involved in the study, with 70.9% being from the central area of Jordan. A considerable number of the participants (52.4%) had bachelor’s degrees and were mostly female. Their average age was 29 ± 7.44 years. Our results showed that many pharmacists dispense 3 mg Liraglutide injection for weight loss and 93% of pharmacists saw a real improvement in the weight loss of patients using the drug. However, our study revealed that many pharmacists(62.3%) were agreed to dispense the drug over-the-counter without a medical prescription and unaware of the risks and side effects of injecting Liraglutide including vitamin D deficiency (21%), hypoglycemia (16%), fatigue (10%), pancreatitis (7%), and hyperthyroidism (5%). Furthermore, the study showed the importance of pharmacists’ awareness in preventing and controlling the side effects of Liraglutide injection.

Abstract 312 | PDF Downloads 269

References

1. Al-Shawabkeh, J. D., Al-Nadaf, A. H., Dahabiyeh, L. A. & Taha, M. O. Design, synthesis and structure-activity relationship of new HSL inhibitors guided by pharmacophore models. Med. Chem. Res.2014; 23:127–145. https://doi.org/10.1007/s00044-013-0616-2
2. Hendricks EJ. Off-label drugs for weight management. Diabetes, metabolic syndrome and obesity: targets and therapy. 2017;10:223-34. https://doi.org/10.2147/dmso.s95299
3. WHO. Malnutrition 2020. Available from: https://www.who.int/news-room/questions-and-answers/item/malnutrition
4. Rabkin S, Campbell H. Comparison of reducing epicardial fat by exercise, diet or bariatric surgery weight loss strategies: a systematic review and meta‐analysis. Obesity reviews. 2015;16(5):406-15. https://doi.org/10.1111/obr.12270
5. Dahlqvist S, Ahlén E, Filipsson K, Gustafsson T, Hirsch IB, Tuomilehto J, et al. Variables associated with HbA1c and weight reductions when adding liraglutide to multiple daily insulin injections in persons with type 2 diabetes (MDI Liraglutide trial 3).
BMJ Open Diabetes Research and Care. 2018;6(1):e000464. https://doi.org/10.1136/bmjdrc2017-000464
6. Matza LS, Boye KS, Currie BM, Paczkowski R, Lando LF, Mody R, et al. Patient perceptions of injection devices used with dulaglutide and liraglutide for treatment of type 2 diabetes. Current Medical Research and Opinion. 2018;34(8):1457-64.
https://doi.org/10.1080/03007995.2018.1465903
7. Overgaard RV, Petri KC, Jacobsen LV, Jensen CB. Liraglutide 3.0 mg for weight management: a population pharmacokinetic analysis. Clinical pharmacokinetics. 2016;55:1413-22. https://doi.org/10.1007/s40262-016-0410-7
8. Whitten JS. Liraglutide (Saxenda) for weight loss. American family physician. 2016; 94(2):161-6. https://doi.org/10.1001/jama.2016.2083
9. Zhang P, Liu Y, Ren Y, Bai J, Zhang G, Cui Y. The efficacy and safety of liraglutide in the obese, non-diabetic individuals: a systematic review and meta-analysis. African Health Sciences. 2019;19(3):2591-9. https://doi.org/10.4314/ahs.v19i3.35
10. Almandoz JP, Lingvay I, Morales J, Campos C. Switching between glucagon-like peptide-1 receptor agonists: rationale and practical guidance. Clinical Diabetes. 2020;38(4):390-402. https://doi.org/10.2337/cd19-0100
11. Pi-Sunyer, X. et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. N. Engl. J. Med.2015;373:11–22. https://doi.org/10.1056/NEJMoa1411892
12. Bruun, J. M. Pharmacotherapy for obesity. Ugeskr. Laeger.2016; 178: 472–477. PMID: 27808050.
13. Mehta A, Marso SP, Neeland I. Liraglutide for weight management: a critical review of the evidence. Obesity science & practice. 2017;3(1):3-14. https://doi.org/10.1002/osp4.84
14. Abutaima R, Barakat M, Sawan HA, ALomari S, Mhaidat N. Jordanian Population Knowledge, Attitude and Practices on the Uses of Antidiabetics for Weight Loss Purposes: A Cross Sectional Study.Research Square; 2023. https://doi.org/10.21203/rs.3.rs-3325697/v1
15. Alhomoud FK, Basil M, Bondarev A. Knowledge, attitudes and practices (KAP) relating to dietary supplements among health sciences and non-health sciences students in one of the universities of United Arab Emirates (UAE). Journal of clinical and diagnostic research: JCDR. 2016;10(9):JC05. https://doi.org/10.7860/jcdr/2016/19300.8439
16. Al-Shawabkeh, J. D., Laban, N. A., Husein, N. & Jaber, D. Knowledge and practice in Jordan regarding the outbreak and prevention of COVID-19: a questionnaire-based study. Trop. J. Pharm. Res. 2023;22:847–857. http://doi.org/10.4314/tjpr.v22i4.X
17. Apperley, L. J., Gait, L., Erlandson-Parry, K., Laing, P. & Senniappan, S. Liraglutide combined with intense lifestyle modification in the management of obesity in adolescents. J. Pediatr. Endocrinol. Metab.2021;34: 613–618. http://doi.org/10.1515/jpem-
2020-0714.
18. Blonde, L. The safety and efficacy of liraglutide with or without oral antidiabetic drug therapy in type 2 diabetes : an overview of the LEAD 1 – 5 studies.2009;11(5): 26–34. https://doi.org/10.1111/j.1463-1326.2009.01075.x.
19. Yu, J., Lee, J., Lee, S. H., Cho, J. H. & Kim, H. S. A Study on Weight Loss Cause as per the Side Effect of Liraglutide. Cardiovasc.Ther. 2022;1:1-8. https://doi.org/10.1155/2022/5201684
20. Garvey, W. T. et al. Efficacy and safety of liraglutide 3.0 mg in individuals with overweight or obesity and type 2 diabetes treated with basal insulin: The SCALE insulin randomized controlled trial. Diabetes Care. 2020; 43:1085–1093. https://doi.org/10.2337/dc19-1745
21. Federici MO, McQuillan J, Biricolti G, Losi S, Lebrec J, Richards C, et al. Utilization patterns of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus in Italy: a retrospective cohort study. Diabetes Therapy. 2018;9:789-801.
https://doi.org/10.1007/s13300-018-0396-2
22. Myshko, D. No Title. Myshko, Denise. ‘Real-World Study Finds Low Patient Adherence Weight Loss Drugs.’ Formul. Watch. 14 July 2023,p. NA. Gale Acad. OneFile, link.gale.com/apps/doc/A776920967/AONE?u=anon~b8a9c843&sid=googleScholar&xid=b2c35ad. Accessed 21 Feb. 2024.
23. Barnard-Kelly, K. et al. Liraglutide and the management of overweight and obesity in people with severe mental illness: qualitative sub-study. BMC Psychiatry. 2022; 22:1–8. https://doi.org/10.1186/s12888‑021‑03666‑5
24. Hernandez, I. & Sullivan, S. D. Net prices of new antiobesity medications. Obesity. 2024; 32:472–475. https://doi.org/10.1002/oby.23973